Fig. 2

Abundance of Treg cells is increased in B lymphoma-bearing animals. A Schematic diagram showing the establishment of a murine B lymphoma model. Six-week-old female BALB/c mice were subcutaneously inoculated with A20 cells (5 × 10⁶ cells in 150 μL of PBS per mouse, n = 5) or PBS (n = 5) as indicated. The mice were killed and tumor and immune organs were collected. B, C Foxp3⁺Treg percentages among CD4⁺T cells in spleen (SP), peripheral blood (PB), lymph node (LN), and bone marrow (BM) from A20 B lymphoma group (BL) and control group (NC). D Tumor growth curves to conform the increasing proportion of Tregs over time while the tumor progressed. n = 3. E Representative flow cytometric analysis of CD62L^low effector Tregs frequencies in spleen, peripheral blood, lymph node, and bone marrow from A20 B lymphoma group (BL) and control group (NC). F effector Treg percentages among CD4⁺T cells in spleen, peripheral blood, lymph node, bone marrow and tumor tissue from A20 B lymphoma group and control group. *P < 0.05; **P < 0.01, ***P < 0.001. In C, p values were determined by two-way ANOVA; In F, p values were determined by two-sided unpaired t-test; data are presented as mean values ± SEM